Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZM-02 in Retinitis Pigmentosa
NCT06292650Phase 1Recruiting
- Sponsor
- Zhongmou Therapeutics
- Start
- Feb 2024
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1 trial of ZM-02 in retinitis pigmentosa (RP) (3 arms), sponsored by Zhongmou Therapeutics. Primary endpoints: Incidence of adverse events and serious adverse events at week 52 and Changes in intraocular pressure at week 52. Started Feb 2024; status: recruiting.
02
Drugs
ZM-02
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT06292650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06292650.